公开(公告)号：US08029768B2

公开(公告)日：2011-10-04

申请号：US12048812

申请日：2008-03-14

申请人： Robin Mark Bannister ,  Andrew John McGlashan Richards ,  Julian Clive Gilbert ,  David A. V. Morton ,  John Staniforth

发明人： Robin Mark Bannister ,  Andrew John McGlashan Richards ,  Julian Clive Gilbert ,  David A. V. Morton ,  John Staniforth

IPC分类号： A61K9/12 ,  A61K9/14

CPC分类号： A61K9/0075 ,  A61K9/145 ,  A61K31/00 ,  A61K31/40 ,  A61K31/46 ,  A61K45/06 ,  Y10S514/826 ,  Y10S514/851 ,  A61K2300/00

摘要： A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

摘要翻译： 用于肺部递送的药物组合物包含控制释放制剂中的格隆溴铵，其中，在给药时，格隆溴铵在大于12小时的时间内发挥其药理作用。

公开(公告)号：US20110005518A1

公开(公告)日：2011-01-13

申请号：US12884505

申请日：2010-09-17

申请人： Robert John Speirs ,  Barbara Ann Schaeffler ,  Peter Bruce Challoner

发明人： Robert John Speirs ,  Barbara Ann Schaeffler ,  Peter Bruce Challoner

IPC分类号： A61K31/7036 ,  A61K9/12 ,  A61P31/04 ,  A61M15/00

CPC分类号： A61K51/0497 ,  A61K9/0078 ,  A61K31/7036 ,  A61K51/0491 ,  Y10S514/851 ,  Y10S514/958

摘要： A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.

摘要翻译： 患有支气管炎感染的患者通过向患者施用小于约4.0ml的剂量的雾化气雾剂制剂来治疗，其包含约60至约200mg / ml的氨基糖苷类抗生素例如妥布霉素， 生理上可接受的载体在小于约10分钟的时间段内。 还提供了用于储存和递送氨基糖苷类抗生素制剂的单位剂量装置。

公开(公告)号：US20100286256A1

公开(公告)日：2010-11-11

申请号：US12722136

申请日：2010-03-11

申请人： Horst Fischer ,  Beate Illek

发明人： Horst Fischer ,  Beate Illek

IPC分类号： A61K31/352 ,  A61K31/12 ,  A61P1/12

CPC分类号： A61K31/05 ,  A61K31/352 ,  A61K31/375 ,  A61K31/7048 ,  A61K45/06 ,  Y10S514/826 ,  Y10S514/851 ,  A61K2300/00

摘要： Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.

摘要翻译： 提供了用于治疗囊性纤维化，哮喘和以氯化物运输有缺陷为特征的其它病症的组合物和方法。 组合物包含一种或多种化合物，例如能够刺激上皮组织中的氯化物转运的黄酮和/或异黄酮，抗坏血酸和/或其衍生物。 治疗方法包括将这种组合物给予（例如口服或经吸入）给患有囊性纤维化，哮喘和/或响应于氯化物转运刺激的另一种病症的患者。

公开(公告)号：US07816374B2

公开(公告)日：2010-10-19

申请号：US12151735

申请日：2008-05-08

申请人： Gerald J. Gleich ,  Loren W. Hunt, Jr.

发明人： Gerald J. Gleich ,  Loren W. Hunt, Jr.

IPC分类号： A61K31/47 ,  A61K31/445

CPC分类号： A61K31/4453 ,  A61K31/167 ,  A61K31/24 ,  A61K31/245 ,  A61K31/445 ,  A61K31/47 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/87

摘要： A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

摘要翻译： 通过局部施用需要这种治疗的哺乳动物，提供有效量的局部麻醉剂如利多卡因或其药学上可接受的盐来治疗嗜中性粒细胞相关性肺疾病如慢性阻塞性肺疾病的治疗方法 。

公开(公告)号：US20090181100A1

公开(公告)日：2009-07-16

申请号：US12320431

申请日：2009-01-26

申请人： H. William Bosch ,  Kevin D. Ostrander ,  Eugene R. Cooper

发明人： H. William Bosch ,  Kevin D. Ostrander ,  Eugene R. Cooper

IPC分类号： A61K9/14 ,  A61K9/12

CPC分类号： A61K9/0078 ,  A61K9/0075 ,  A61K9/008 ,  A61K9/146 ,  A61K9/1694 ,  A61K9/19 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/872

摘要： There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.

摘要翻译： 本发明公开了纳米颗粒气雾剂配方的水性分散体，干燥粉末纳米颗粒气溶胶配制剂，基于推进剂的气溶胶制剂，在气溶胶递送装置中使用制剂的方法，以及制备这些制剂的方法。 含水分散体或干粉配方的纳米颗粒包含在其表面上具有表面改性剂的不溶性药物颗粒。

公开(公告)号：US07524517B2

公开(公告)日：2009-04-28

申请号：US10542555

申请日：2004-01-20

申请人： Erik Schwiebert ,  Akos Zsembery

发明人： Erik Schwiebert ,  Akos Zsembery

IPC分类号： A61K33/30 ,  A61K31/315 ,  A61K31/7076 ,  A61P11/00 ,  A61P11/06

CPC分类号： A61K31/7088 ,  A61K31/315 ,  A61K31/7072 ,  A61K33/30 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/924 ,  A61K2300/00

摘要： This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).

摘要翻译： 本发明一般涉及增加哺乳动物细胞中胞质Ca 2+水平的方法，其包括使P2X受体Ca 2+进入通道或细胞中任何和所有其它Ca 2+进入通道或机制与有效量的小分子接触，以及包含小分子 分子在递送系统中。 本发明作为治疗气道疾病（如囊性纤维化和哮喘），肺和气道疾病（如常见感冒病原体或过敏原引起的疾病），肾脏疾病和肾脏疾病的方法具有广泛适用性 高血压疾病（如多囊肾病和盐敏感性高血压综合征）和内分泌疾病（如糖尿病）。

公开(公告)号：US20090054485A1

公开(公告)日：2009-02-26

申请号：US12151735

申请日：2008-05-08

申请人： Gerald J. Gleich ,  Loren W. Hunt, JR.

发明人： Gerald J. Gleich ,  Loren W. Hunt, JR.

IPC分类号： A61K31/445 ,  A61K31/24 ,  A61P11/00

CPC分类号： A61K31/4453 ,  A61K31/167 ,  A61K31/24 ,  A61K31/245 ,  A61K31/445 ,  A61K31/47 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/87

摘要： A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

摘要翻译： 通过局部施用需要这种治疗的哺乳动物，提供有效量的局部麻醉剂如利多卡因或其药学上可接受的盐来治疗嗜中性粒细胞相关性肺疾病如慢性阻塞性肺疾病的治疗方法 。

公开(公告)号：US20070218013A1

公开(公告)日：2007-09-20

申请号：US11596566

申请日：2005-05-02

申请人： William Baker ,  David MacLeod

发明人： William Baker ,  David MacLeod

IPC分类号： A61K9/14 ,  A61K9/12

CPC分类号： A61K31/7008 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/19 ,  A61K31/665 ,  A61K31/7036 ,  A61K45/06 ,  A61M11/00 ,  A61M11/005 ,  B65D85/00 ,  Y02A50/473 ,  Y10S514/851 ,  Y10T436/107497 ,  A61K2300/00

摘要： A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

摘要翻译： 描述了通过气雾化递送的磷霉素加妥布霉素组合制剂。 含有有效量的磷霉素加妥布霉素的浓缩磷霉素妥布霉素组合制剂能够抑制易感细菌。 磷霉素和妥布霉素分别配制在双安瓿中，使得当重新配制时，pH值在4.5-8.0之间或干粉末。 用喷雾或超声雾化器（或等效的）或干粉吸入器产生的具有主要在1至5微米之间的质量中等平均直径的气溶胶递送的制剂的治疗呼吸道感染的方法。

公开(公告)号：US20060142208A1

公开(公告)日：2006-06-29

申请号：US11354740

申请日：2006-02-15

申请人： Richard Boucher

发明人： Richard Boucher

IPC分类号： A61K31/70 ,  A61K31/28 ,  A61K31/285 ,  A61K31/205 ,  A61K31/198

CPC分类号： A61K9/0078 ,  A61K9/008 ,  A61K31/4965 ,  A61K31/70 ,  Y10S514/826 ,  Y10S514/851

摘要： Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.

公开(公告)号：US06989156B2

公开(公告)日：2006-01-24

申请号：US10128208

申请日：2002-04-23

申请人： Scott H. Gillis

发明人： Scott H. Gillis

IPC分类号： A61K9/14 ,  A61K9/08 ,  A61K33/00 ,  A61K33/24 ,  A61K33/38

CPC分类号： A61K9/0024 ,  A01N59/16 ,  A61K9/0019 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/14 ,  A61K9/7007 ,  A61K33/24 ,  A61K33/38 ,  A61K33/40 ,  A61K47/34 ,  A61K47/38 ,  A61L15/46 ,  A61L17/145 ,  A61L27/30 ,  A61L29/10 ,  A61L31/082 ,  A61L2300/102 ,  A61L2300/104 ,  A61L2300/404 ,  A61L2300/452 ,  A61L2300/606 ,  A61L2300/624 ,  A61L2300/63 ,  Y10S424/15 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/829 ,  Y10S514/83 ,  Y10S514/849 ,  Y10S514/851 ,  Y10S514/853 ,  Y10S514/861 ,  Y10S514/862 ,  Y10S514/864 ,  Y10S514/865 ,  Y10S514/88 ,  Y10S514/881 ,  Y10S514/882 ,  Y10S514/886 ,  Y10S514/887 ,  Y10S514/90 ,  Y10S514/901 ,  Y10S514/902 ,  Y10S514/912 ,  Y10S514/914 ,  Y10S514/925 ,  Y10S514/931 ,  Y10S514/932 ,  Y10S514/933 ,  Y10S514/934 ,  Y10S514/944 ,  Y10S514/951 ,  Y10S514/953 ,  Y10S514/954 ,  Y10S514/956 ,  Y10S514/958 ,  Y10S514/964 ,  Y10S514/965 ,  Y10S514/966 ,  Y10S514/967 ,  Y10S514/968 ,  Y10S514/969 ,  Y10T428/31855 ,  A61K2300/00 ,  A01N25/04 ,  A01N25/10 ,  A01N25/12

摘要： Therapeutic treatments using the direct application of selected structures of antimicrobial metals in free-standing powder form, solution form and/or suspension form in therapeutically effective amounts. The selected structures of antimicrobial metals serve as an antimicrobial agent, an anti-inflammatory agent, an immuno modulator agent, an enzyme modulator agent, and/or an anti-tumor agent, for human and/or animal use.